According to results of a systematic review and meta-analysis, overall survival was similar between allogeneic and autologous hematopoietic stem cell transplant (HSCT) among patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL). These findings were published in JAMA Network Open.

To assess which HSCT approach is more efficacious, publication databases were searched through October of 2020 for studies of HSCT as treatment for patients with R/R-PTCL.

A total of 16 studies of autologous HSCT (885 patients) and 16 studies of allogeneic HSCT (880 patients) were included.

Continue Reading

The autologous HSCT recipients were aged 4 to 73 years, with follow-ups of 1 to 278 months. The allogeneic HSCT recipients were aged 16 to 74 years, with follow-ups of 0.3 to 195 months.

Three-year overall survival was 0.50 (95% CI, 0.41-0.60; I2, 71%; P <.01) and 0.52 (95% CI, 0.47-0.59; I2, 74%; P <.01), and progression-free survival was 0.42 (95% CI, 0.35-0.51; I2, 45%; P =.08) and 0.42 (95% CI, 0.37-0.49; I2, 71%; P <.01) for allogeneic and autologous HSCT, respectively.

Five-year overall survival was 0.54 (95% CI, 0.47-0.62; I2, 0%; P =.64) and 0.54 (95% CI, 0.48-0.61; I2, 47%; P =.04), and progression-free survival was 0.48 (95% CI, 0.40-0.56; I2, 5%; P =.35) and 0.44 (95% CI, 0.33-0.55; I2, 81%; P <.01), respectively.

Transplantation-related mortality at 3 years was higher in the allogeneic HSCT group (32%; 95% CI, 27%-37%) compared with the autologous HSCT group (7%; 95% CI, 2%-23%).

This analysis comprised data mostly from single-arm studies, so direct comparisons could not be evaluated.

These data indicated overall and progression-free survival was similar for both HSCT procedures in patients with R/R-PTCL. Although, autologous HSCT was associated with a lower transplant-related mortality.


Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(5):e219807. doi:10.1001/jamanetworkopen.2021.9807

This article originally appeared on Hematology Advisor